Sun, Dec 28, 2014, 12:36 AM EST - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Amarantus Bioscience Holdings, Inc Message Board

garydaemon 125 posts  |  Last Activity: 7 hours ago Member since: Jan 3, 2009
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    Next steps for CTSO

    by sbenni1 21 hours ago
    garydaemon garydaemon 7 hours ago Flag

    Also Drugsorb
    This is the brand and trademark page for DRUGSORB which was created on February 6th, 2014 by Cytosorbents, Inc.
    Medical devices, namely absorption and polymeric absorption materials for removing drugs in the case of drug overdose or therapeutic agents from blood and blood fractions

  • Reply to

    Next steps for CTSO

    by sbenni1 21 hours ago
    garydaemon garydaemon 7 hours ago Flag

    new filters
    ContrastSorb
    On Thursday, February 06, 2014, a U.S. federal trademark registration was filed for CONTRASTSORB by CYTOSORBENTS, INC.,
    The description provided to the USPTO for CONTRASTSORB is Medical devices, namely absorption and polymeric absorption materials for removing radiologic contrast materials from blood and blood fractions.

  • garydaemon garydaemon Dec 20, 2014 6:41 PM Flag

    Imagine what will happen if the next Ebola patient has a Cytosorb filter to battle the cytokine storm these patients face.

    We initiated a continuous haemodiafiltration (Fresenius CiCa Multifiltrate; Fresenius, Bad Homburg, Germany). The calcium-citrate approach chosen bore less of a risk for haemorrhage. This therapy was given continuously up to day 27. Urine production restarted on day 22. Because phosphate was still elevated, the patient was continued with intermittent haemodialysis every 48 h until day 37.

  • Reply to

    NBC Retraction

    by jbcoopertire Dec 19, 2014 10:05 PM
    garydaemon garydaemon Dec 19, 2014 10:31 PM Flag

    NBC is a joke, unlike a true medical journal that only publishes the facts.
    Another Lancet Ebola paper:
    Their attempt to administer a course of favipiravir was abandoned quickly due to problems with dosing, underscoring the difficulties of giving drugs to patients with EVD. A virus-binding haemofiltration cartridge was also tried, but seems to have had little effect on viraemia.

  • Reply to

    Misleading....but technically true ?

    by sportacus95 Dec 19, 2014 9:41 AM
    garydaemon garydaemon Dec 19, 2014 9:48 AM Flag

    The first filter used from day 9-27 did a good job

  • Reply to

    Today

    by mak.orlfl Dec 19, 2014 9:04 AM
    garydaemon garydaemon Dec 19, 2014 9:37 AM Flag

    Vascular leakage can lead to multiorgan failure induced by oedematous tissue damage. The question of whether the release of cytokines or interaction of viral proteins with the endothelium itself causes the leakage in Ebola virus disease is still under debate. Early in infection, the cytokines released from infected macrophages are thought to induce leakage

  • Reply to

    Today

    by mak.orlfl Dec 19, 2014 9:04 AM
    garydaemon garydaemon Dec 19, 2014 9:29 AM Flag

    I expect a jump on the Aethlon filter report, Fresenius used a filter on that patient and should another patient be treated most likely it will be a Cytosorb filter in its place.

  • Reply to

    The science won't lie...

    by ggroce3333 Dec 19, 2014 8:06 AM
    garydaemon garydaemon Dec 19, 2014 8:45 AM Flag

    yes and it said the filter did not remove virus,,,,
    It did not remove enough to be of use.
    First the patient was stabilized before they added the second filter, the Fresenius filter removed the virus also if you had read the Lancet.

  • Reply to

    The science won't lie...

    by ggroce3333 Dec 19, 2014 8:06 AM
    garydaemon garydaemon Dec 19, 2014 8:36 AM Flag

    Africa is hopeless for the proper treatment, I have yet to hear of a dialysis machine in use in Sierra Leone. I also read yesterday a building used for storing one of the experimental drugs had burned down and thousands of doses lost. Why was this doctor not flown out like the others?

  • Reply to

    The science won't lie...

    by ggroce3333 Dec 19, 2014 8:06 AM
    garydaemon garydaemon Dec 19, 2014 8:29 AM Flag

    This information comes directly from a top medical journal the "Lancet" published yesterday from the 10 top doctors that treated him.

  • Reply to

    Frankfurt says it didn't work..... Ruh-Row

    by oxycoldone Dec 18, 2014 8:47 PM
    garydaemon garydaemon Dec 18, 2014 11:43 PM Flag

    It is fact and it is published in the Lancet, also there was another filter used from day 9-27
    it was a Fresenius CiCa Multifiltrate

  • Reply to

    Frankfurt says it didn't work..... Ruh-Row

    by oxycoldone Dec 18, 2014 8:47 PM
    garydaemon garydaemon Dec 18, 2014 10:39 PM Flag

    This has been taken from the Lancet today:

    On day 13—after the haemodynamic situation had already stabilised—we used a haemofiltration cartridge (Haemopurifier; Aethlon, San Diego, CA, USA) for 6·5 h upstream to the regular system. This cartridge is designed to bind viral glycoproteins by lectin affinity. This one-time use was well tolerated. PCR measurements taken directly before and after the use showed virus loads of 2·29 × 105 copies per mL and 7·66 × 104 copies per mL, respectively. This difference of less than a factor of 3 is within the technical variability range of the RNA PCR assay for Ebola virus and cannot be judged as a notable decrease.

  • Reply to

    Why this deal is so important

    by mbs1088 Dec 16, 2014 3:18 AM
    garydaemon garydaemon Dec 17, 2014 8:15 AM Flag

    Fresenius has agreed not to compete with the Company regarding the production or distribution of a competitive product in the Territory.
    Between Fresinius and the Cytosorbents sales team it appears Europe will be locked up to outside competition for a few years.

    Sentiment: Buy

  • Reply to

    Why this deal is so important

    by mbs1088 Dec 16, 2014 3:18 AM
    garydaemon garydaemon Dec 16, 2014 8:51 AM Flag

    If it could only be used on a new Ebola patient and direct some of that new Ebola funding our way.

    In terms of Ebola, CytoSorbents is currently in five of seven major hospitals in Germany that are prepared to accept Ebola patients. We have communicated with these hospitals and providers in these hospitals and have made CytoSorb an option to potentially treat patients should they wind up being admitted to these hospitals. We have also had communications with the World Health Organization, the Centers for Disease Control, the FDA, the National Institutes of Allergy and Infectious Disease, [indiscernible] of the Department of Defense, treatment hospitals in the United States and others.

    Sepsis led to severe illness when the viral load was already decreasing, which suggests that sepsis may contribute substantially to the mortality observed in the current outbreak of Ebola, specifically with regard to deaths occurring late after disease onset.

  • Reply to

    Most interesting

    by floydtrainer Dec 15, 2014 5:17 PM
    garydaemon garydaemon Dec 15, 2014 10:41 PM Flag

    We sell directly to these other countries
    CytoSorb® is sold directly in Germany, Austria and Switzerland, with expanding distribution in the United Kingdom, Ireland, the Netherlands, Turkey, India, Russia, Taiwan, Kingdom of Saudi Arabia, United Arab Emirates, Bahrain, Kuwait, Qatar, Yemen, Iraq, Jordan and Oman, and now Romania and Moldova.

  • garydaemon garydaemon Dec 15, 2014 8:20 PM Flag

    CytoSorbents is currently in five of seven major hospitals in Germany that are prepared to accept Ebola patients.
    I think so

  • garydaemon garydaemon Dec 8, 2014 7:17 PM Flag

    Conducted protocols then-
    Future clinical trials will include a biological skin substitute to treat severe burns; an extracorporeal device to treat sepsis; a drug to treat muscle atrophy in burn patients; and the use of a mesh graft with spray on skin.

  • Reply to

    Aemd

    by fudruckker Dec 6, 2014 8:50 AM
    garydaemon garydaemon Dec 6, 2014 5:41 PM Flag

    Yet Emerson did the same thing while using a Gambro HF 1400 filter, all of these patients were given multiple experimental treatments along with blood from survivors. At this point it is impossible to say if any one treatment will come out the winner.

  • garydaemon garydaemon Dec 6, 2014 3:56 PM Flag

    Recent cures in Europe:

    (Reuters) - A Cuban doctor who received experimental treatment for Ebola in a Geneva hospital has made a full recovery and left Switzerland to be reunited with his family, the hospital said on Saturday.

    Felix Baez, 43, was one of 256 Cuban doctors and nurses who went to West Africa to treat patients from the worst outbreak of the virus on record, which has killed more than 6,000 people.

    Soon after arriving in Geneva, Baez received the Canadian experimental treatment ZMab, a precursor to the Ebola drug ZMapp, which has been used to treat several U.S. patients.

    "Two days afterwards he was already much better," Geneva's chief medical officer Jacques-André Romand told Reuters, adding that the same drug had been sent to Rome to treat an Italian doctor battling the virus.

    A hospital spokeswoman said he received both ZMab and the untested flu drug favipiravir, made by Japan's Fujifilm, which the WHO has included on a list of potential Ebola treatments.

  • Reply to

    PR

    by firestart57 Dec 5, 2014 10:09 PM
    garydaemon garydaemon Dec 6, 2014 10:45 AM Flag

    Cytosorbents Corp - FORM S-1/A - November 12, 2014
    For the nine months ended September 30, 2014, we generated revenue of approximately $3,249,000 as compared to revenues of approximately $1,544,000, for the nine months ended September 30, 2013, an increase of approximately $1,424,000 or 110%. Revenue from product sales was approximately $2,264,000 in the nine months ended September 30, 2014, as compared to approximately $508,000 in the nine months ended September 30, 2014, an increase approximately $1,756,000 or 346%. This increase in sales is a result of the efforts of our four person sales team which was established in August 2012 and was expanded in 2014 to seven people, as well as sales to distributors in other parts of Europe and elsewhere in the world.

AMBS
0.084-0.004(-4.44%)Dec 26 3:58 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Prothena Corporation plc
NASDAQFri, Dec 26, 2014 4:00 PM EST
Rice Energy Inc.
NYSEFri, Dec 26, 2014 4:02 PM EST